News

1 to 9 of 11 results

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

23-07-2014

Canadian clinical-stage cardiovascular specialist Resverlogix Corp has announced results it believes…

CanadaCardio-vascularDiabetesNephrology and HepatologyPharmaceuticalResearchResverlogixRVX-208

Cytori licenses Asia-Pacific cardiovascular, renal and diabetes markets to Lorem Vascular for up to $531 million

05-11-2013

San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership…

Asia-PacificBiotechnologyCardio-vascularCytori TherapeuticsDiabetesLicensingLorem VascularMergers & AcquisitionsNephrology and Hepatology

US FDA accepts NDAs for Otsuka's tolvaptan and BTG's Varisolve

12-04-2013

Japanese mid-sized drugmaker Otsuka Pharmaceutical (TYO: 4578) says that the US Food and Drug Administration…

BTGCardio-vascularNephrology and HepatologyNorth AmericaOtsukaPharmaceuticalRare diseasesRegulationtolvaptanVarisolve

High potency statins pose significantly higher risk of kidney injury than low potency, say experts

20-03-2013

Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalized…

Cardio-vascularNephrology and HepatologyPharmaceuticalResearch

Japan launches for Lotriga and Argamate

11-01-2013

Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients

11-06-2012

Amgen (Nasdaq: AMGN), the world's largest independent biotech company, announced top-line results on…

AmgenBiotechnologyCardio-vascularMimparaNephrology and HepatologyResearchSensipar

1 to 9 of 11 results

Back to top